New Leaf Venture Partners’s Sage Therapeutics SAGE Stock Holding History

New Leaf Venture Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-25,000	Closed	-$4.12M	–	16
2017 Q4	$4.12M	Sell	25,000 -19,872	-44%	-$1.93M	1.93%	9
2017 Q3	$2.8M	Sell	44,872 -23,000	-34%	-$1.81M	1.3%	10
2017 Q2	$5.41M	Sell	67,872 -31,251	-32%	-$2.26M	3.8%	8
2017 Q1	$7.04M	Sell	99,123 -15,000	-13%	-$879K	3.61%	7
2016 Q4	$5.83M	Sell	114,123 -18,551	-14%	-$874K	4.17%	7
2016 Q3	$6.11M	Sell	132,674 -24,284	-15%	-$988K	4.4%	8
2016 Q2	$4.73M	Buy	156,958 +14,388	+10%	+$480K	4.07%	9
2016 Q1	$4.57M	Buy	+142,570	New	+$5.02M	4.14%	8
2015 Q4	–	Sell	-23,829	Closed	-$1.01M	–	12
2015 Q3	$1.01M	Buy	+23,829	New	+$1.47M	0.87%	11
2015 Q2	–	Sell	-43,770	Closed	-$2.2M	–	15
2015 Q1	$2.2M	Buy	43,770 +8,400	+24%	+$361K	1.49%	12
2014 Q4	$1.29M	Buy	+35,370	New	+$1.32M	0.63%	12

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

New Leaf Venture Partners's SAGE Position: Q1 2018 in Review

New Leaf Venture Partners sold out of Sage Therapeutics (SAGE) in Q1 2018, closing a stake of 25,000 shares — an estimated $4.12M sold.

New Leaf Venture Partners first reported a position in SAGE in Q4 2014 and held it in 11 quarters. The position peaked at $7.04M in Q1 2017. 250 funds tracked by Wall St. Rank hold SAGE as of Q1 2018.

New Leaf Venture Partners reported no remaining Sage Therapeutics position as of Q1 2018 after selling out during the quarter.
New Leaf Venture Partners sold 25,000 Sage Therapeutics shares in Q1 2018, an estimated $4.12M.
New Leaf Venture Partners first reported a position in Sage Therapeutics in Q4 2014 and held it in 11 quarters.
New Leaf Venture Partners's Sage Therapeutics position peaked at $7.04M in Q1 2017.
250 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2018.

Based on New Leaf Venture Partners's 13F filing for Q1 2018, filed 15 May 2018.